Arovella Therapeutics Ltd宣布已正式向美国食品药品监督管理局提交Ala-101的新药临床试验申请,该项申请旨在启动该药物的首次人体一期临床试验。这一重要进展标志着公司创新疗法开发迈入新的阶段。
Arovella Therapeutics Ltd宣布已正式向美国食品药品监督管理局提交Ala-101的新药临床试验申请,该项申请旨在启动该药物的首次人体一期临床试验。这一重要进展标志着公司创新疗法开发迈入新的阶段。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.